At ASCO 2017, Cytel trial design experts joined our medical and academic colleagues to share the most recent innovations in cancer research.

Our co-authored poster presentation with TRACON Pharmaceuticals drew interest from statisticians and clinicians from sponsor companies planning studies with challenges of heterogeneous treatment effect since a population enrichment design can help mitigate development risk in such situations.

Complete the form to download a pdf copy of the poster:

TAPPAS: Adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS)